) and partner Genmab recently announced encouraging top-line data
from a phase III study (n = 447) which is evaluating oncology
drug, Arzerra (ofatumumab). The study compared the efficacy of
Arzerra as an adjunct to another oncology drug at Glaxo, Leukeran
(chlorambucil) in treatment-naive chronic lymphocytic leukaemia
(CLL) patients versus Leukeran alone.
GLAXOSMITHKLINE (GSK): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
The study met its primary endpoint of progression free survival
(PFS/the time a patient lived without worsening of their
disease). Data from the study was assessed by an independent
review committee. In the Arzerra + Leukeran arm of the study,
median PFS of 22.4 months was observed as compared to 13.1 months
in the Leukeran arm, representing an improvement of 9.3 months.
We note Arzerra is already approved, since Oct 2009, for the
treatment of patients with CLL refractory to
) Campath (alemtuzumab) and Fludara (fludarabine).
We note that Glaxo's oncology portfolio received a boost recently
when two new melanoma drugs, Tafinlar (dabrafenib) and Mekinist
(trametinib) received the US Food and Drug Administration (FDA)
approval. While Tafinlar was approved for use in BRAF V600E
mutation-positive unresectable or metastatic melanoma patients,
Mekinist received clearance for the treatment of patients
suffering from unresectable or metastatic melanoma with BRAF
V600E or V600K mutations.
Glaxo carries a Zacks Rank #3 (Hold). We are pleased with Glaxo's
label expansion efforts. Moreover, Glaxo boasts of a robust
pipeline. A number of pipeline-related news is expected in the
coming quarters. Given the declining sales from generic
competition, we believe Glaxo's pipeline must deliver. Companies
that currently look attractive include
). Both carry a Zacks Rank #1 (Strong Buy).